Dr Anders Gustavsson is co-founding partner at Quantify, and holds an MSc from the Stockholm School of Economics and a PhD in Health Economics from Karolinska Institutet, Sweden. During his PhD studies, Anders developed new methods for the economic evaluation of treatment for Alzheimer’s disease. Anders has worked with health economics since 2005, first as researcher at European Health Economics and from 2008 as Associate Director at i3 Innovus, leading a research team in neuroscience. In 2011, he co-founded Quantify Research, a consultancy in health economics, outcomes research and real world evidence. As a consultant, Anders has worked with pharma and biotech companies, patient organisations, health care providers and government institutions. He has a broad competence within research and has co-authored over 30 peer-reviewed papers including registry studies, prospective cohorts, within-trial analysis, patient- and caregiver preference studies and decision analytic models. Anders was coordinator and first author of the European study on the costs of brain disorders (2010), initiated by European Brain Council. He is affiliated to Karolinska Institutet and a co-organiser of the International Pharmaco-Economic Conference on Alzheimer’s disease (IPECAD).